Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Hepatol Res. 2014 Jun 4;45(3):305–314. doi: 10.1111/hepr.12352

Figure 1.

Figure 1

Amitriptyline (TCA) treatment decreases hepatic acidic sphingomyelinase (ASM) activity. Hepatic ASM activity was determined after 8 weeks of treatment. TCA treatment decreased ASM activity compared to vehicle and CCl4 treatment. n=4–6 per group. Data are expressed as mean and SEM. *p<0.05 compared to all other groups.